- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06129019
the Effect of Reiki Application on Depression, Anxiety and Physical Activity in Patient With Multiple Sclerosis
Investigation of the Effect of Reiki Application on Depression, Anxiety and Physical Activity in Individuals Diagnosed With Relapsing-Remitting Multiple Sclerosis
During Reiki application, individuals may report feeling a slight warm sensation under and near the therapist's hand. The only rule in Reiki practice is that the individual must give permission to the practitioner to facilitate the flow of energy. The person receiving Reiki during the application does not have to believe in Reiki. Because Reiki is universal life energy and is available to everyone. Reiki is generally safe and no serious side effects have been reported. Reiki practice in the last 10 years; It is increasing among physicians, nurses and other healthcare professionals.
This study was planned to investigate the effect of reiki application on depression, anxiety and physical activity in individuals diagnosed with Relapsing-Remitting Multiple Sclerosis.
Geri bildirim gönder Yan paneller
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Elazıg, Turkey
- Firat University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Being over 18 years of age
- Having the ability to use technological devices
- Not using Reiki and similar integrative treatment methods
- No verbal communication disability (hearing and speaking)
- Not having a diagnosed psychiatric disorder
- Patients who have been receiving Relapsing-Remitting MS treatment for more than three months
Exclusion Criteria:
- Patients using any complementary alternative treatment methods
- Patients who cannot communicate by phone to participate in remote reiki application
- Patients with autoimmune diseases other than multiple sclerosis
- Patients with communication disabilities
- Patients with another known neurological system disease (dementia, Alzheimer's, etc.).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Experimental:
Reiki application will be done
|
Reiki application will be done
|
|
No Intervention: Control
Reiki application will not be done
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Beck Depression Scale
Time Frame: 4 week
|
The scale was administered to investigate each participant's feelings and attitudes regarding the general depressive state.
Each patient was asked to read several groups of statements and then mark the one statement in each group that best described how he or she felt "during the past week."
BDI, which evaluates four statements describing increasing intensities of depressive symptoms between 0 and 3 points, includes 21 items.
Depressive symptoms were classified as follows: minimal-to-moderate depressive symptoms (range 14 to 19), moderate-to-severe depressive symptoms (range 20 to 29), severe depressive symptoms (range 30 to 63).
|
4 week
|
|
Beck Anxiety Scale
Time Frame: 4 week
|
BAI is a self-rating scale developed by Beck et al. (1988) and used to determine the frequency of anxiety symptoms experienced by individuals.
It is a Likert-type scale consisting of 21 items and scored between 0-3.
Its validity and reliability in Turkey were determined by Ulusoy et al.
|
4 week
|
|
International Physical Activity Survey
Time Frame: 4 week
|
There are some scales that can be used in primary care to evaluate physical mobility.
One of these is the "International Physical Activity Questionnaire", which was developed by the International Consensus Group consisting of researchers from various countries with the support of the World Health Organization and the Center for Disease Control, to be used to measure physical activity and inactivity in 1997 and 1998; (IPAQ)" is a standard tool.
Reliability and/or validity studies were conducted in 14 centers from 12 countries in 2000 for at least two of the four long (IPAQ-long) and four short (IPAQ-SF) forms of the IPAQ.
This scale was adapted into Turkish as long form (UF) and short form (SF) under the name "International Physical Activity Questionnaire (UFAA)" and its validity and reliability study was conducted by Sağlam et al. in 2010
|
4 week
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22/11
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis, Relapsing-Remitting
-
BiogenWithdrawnRelapsing-Remitting Multiple Sclerosis | Relapsing Forms of Multiple Sclerosis
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
Bristol-Myers SquibbActive, not recruitingRelapsing-remitting Multiple Sclerosis (RRMS)Spain
-
Hoffmann-La RochePPD Development, LPActive, not recruitingRelapsing-Remitting Multiple SclerosisUnited States, Spain, Canada, Portugal, India, United Kingdom, Belgium, France, Brazil, Austria, Germany, Hungary, Estonia, Poland, Mexico, Australia, Italy, Ukraine, Serbia, Latvia, Morocco, Argentina, Switzerland, Greece, Romania
-
BiogenWithdrawn
-
BiogenAbbVieTerminatedMultiple Sclerosis | Relapsing-Remitting Multiple SclerosisUnited States, Denmark, Italy, United Kingdom, Czechia, Canada, Hungary, Spain, Australia, Israel, Georgia, Serbia, Russian Federation, Ukraine, India, Poland, Brazil, France, Argentina, Germany, Greece, Ireland, Mexico, Moldova, Republic... and more
-
EMD SeronoPfizerCompletedRelapsing-remitting Multiple SclerosisUnited States, United Kingdom, Argentina, Austria, Brazil, France, Germany, Italy, Netherlands, Russian Federation, Spain, Switzerland
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedRelapsing-Remitting Multiple SclerosisUnited States
-
BiogenTerminatedRelapsing-Remitting Multiple SclerosisUnited States, Spain, Germany, Australia, Sweden, Czechia, France, Italy, United Kingdom
-
Novartis PharmaceuticalsWithdrawnMultiple Sclerosis (Relapsing Remitting)
Clinical Trials on Reiki
-
University of YalovaCompletedNursing | Reiki | İntensive CareTurkey
-
University of YalovaCompleted
-
Mardin Artuklu UniversityCompleted
-
Sultan ÇEÇENCompleted
-
Mersin UniversityTübitakRecruiting
-
Ohio State UniversityCompletedMechanical Ventilation Complication | Complementary Health ApproachUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Autologous Stem Cell TransplantUnited States
-
Ondokuz Mayıs UniversityOndokuz Mayıs UniversityCompleted
-
TC Erciyes UniversityRecruitingDiabetic NeuropathyTurkey
-
Kahramanmaras Sutcu Imam UniversityCompletedNeuropathic Pain Diagnostic Questionnaire (DN4) ≥ 4Turkey